Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CNS Pharmaceuticals, Inc.CNSP · Entity 8048 | Director | November 17, 2025 | November 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CNS Pharmaceuticals, Inc.
Report date November 17, 2025 · Filed November 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $12.48 · Expires 2035-11-17 | Direct | 1,517 |
Reported balance
After 2025-11-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-17 · Grant · Acquired 1,517 · Balance 1,517 F1: The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on June 6, 2025, subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025 (the "Shareholder Approval Date"). F3: Issued in connection with the reporting person's employment with the Company. F2: The options set forth in the table vest in four equal quarterly installments commencing on the Shareholder Approval Date, subject to the reporting person's continued employment on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on June 6, 2025, subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025 (the "Shareholder Approval Date").
F2: The options set forth in the table vest in four equal quarterly installments commencing on the Shareholder Approval Date, subject to the reporting person's continued employment on each vesting date.
F3: Issued in connection with the reporting person's employment with the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 17, 2025 Filed Nov 19, 2025 17:00 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock · Derivative | 1,517 | $0.00 Strike: $12.48 | $0.00 |
DisclosureSEC source: 0001683168-25-008565 · ownership.xml · derivative · entry 1 Mahery Amy · CIK 0002008489 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,517 Underlying: Common Stock · 1,517 shares Expires 2035-11-17 F1 · date: The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on June 6, 2025, subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025 (the "Shareholder Approval Date"). F3 · price: Issued in connection with the reporting person's employment with the Company. F2 · derivative.exercise_date: The options set forth in the table vest in four equal quarterly installments commencing on the Shareholder Approval Date, subject to the reporting person's continued employment on each vesting date. Read SEC document |
| April 08, 2024 Filed Apr 10, 2024 21:53 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantRestricted Stock Units · Derivative | 17,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-24-002290 · ownership.xml · derivative · entry 2 Mahery Amy · CIK 0002008489 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,420 Underlying: Common Stock · 17,500 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company common stock. F2 · price: The awards were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date. F1 · derivative.expiration_date: The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date. Read SEC document |
| April 08, 2024 Filed Apr 10, 2024 21:53 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock · Derivative | 17,500 | Not disclosed Strike: $0.26 | Not disclosed |
DisclosureSEC source: 0001683168-24-002290 · ownership.xml · derivative · entry 1 Mahery Amy · CIK 0002008489 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,920 Underlying: Common Stock · 17,500 shares Expires 2034-04-08 F2 · price: The awards were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 10:28 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock · Derivative | 12,420 | Not disclosed Strike: $0.25 | Not disclosed |
DisclosureSEC source: 0001683168-24-000709 · ownership.xml · derivative · entry 1 Mahery Amy · CIK 0002008489 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,420 Underlying: Common Stock · 12,420 shares Expires 2034-02-01 F2 · price: The options were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The options set forth in this table vest in 36 equal monthly installments succeeding the issuance date, or February 1, 2024, subject to the grantee's continued service on the Company's Board of Directors on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.